Spots Global Cancer Trial Database for Exemestane (Aromasine) + Tamoxifen - Breast Neo-Adjuvant
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Exemestane (Aromasine) + Tamoxifen - Breast Neo-Adjuvant
Official Title: Phase II Study Evaluating the Effectiveness of the Exemestane (Aromasin) With Tamoxifen on the Rate of Clinical Response Menopausal in Patients With Locally Advanced Breast Tumors
Study ID: NCT00919399
Conditions
Study Description
Brief Summary: This is a Phase II non-randomized, open, uncontrolled and bi-centric study of hormonal induction by exemestane (Aromasin) + tamoxifen to evaluate the effectiveness of exemestane (Aromasin) with tamoxifen on the rate of clinical response menopausal in patients with tumors of locally advanced breast. Hormone therapy will be administered at a dose of 25mg/day for exemestane and 20 mg / day for 4 months for tamoxifen.
Detailed Description:
Eligibility
Minimum Age: 60 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: FEMALE
Healthy Volunteers: No
Locations
CHU de Toulouse Rangueil, Toulouse, , France
Institut Claudius Regaud, Toulouse, , France
Contact Details
Name: Henri ROCHE
Affiliation: Institut Claudius Regaud
Role: PRINCIPAL_INVESTIGATOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
